All
Erleada Reduces Risk of Death in Metastatic Prostate Cancer Subset
Erleada reduced the risk of death by more than 20% compared with other treatments in metastatic castration-sensitive prostate cancer.
Subcutaneous Opdivo Similarly Effective, Safe as IV for Advanced ccRCC
Subcutaneous Opdivo showed comparable effectiveness, safety and tolerability to IV Opdivo in advanced clear cell renal cell carcinoma.
Spring Looks Different This Year
What is lovely never dies, but passes into other loveliness, Stardust or seafoam, flower or winged air. ― Thomas Bailey Aldrich
First Patient Treated in Trial of PHST001 for Advanced Solid Tumors
Pheast Therapeutics has treated the first patient in a phase 1 trial of PHST001, a novel macrophage checkpoint inhibitor for advanced solid tumors.
Clinical Trial of NEO100 Recruiting Patients With Malignant Gliomas
A phase 2a clinical trial of NEO100-01 is continuing to recruit patients with malignant gliomas, with full enrollment expected in September.
Nubeqa Combo Improves Outcomes in Metastatic Prostate Cancer
Nubeqa plus hormone therapy improved outcomes in metastatic prostate cancer, reducing disease progression and showing a favorable safety profile.
Expanding Definition of Cancer Survivorship Highlights Need for New Standards
Tara Sweeney, BSN, RN, OCN, CHPN discussed best care for the health and well-being of a person across all stages of their cancer survivorship.
Radiation Therapy Advances Improve Quality of Life for GI Cancer
Advancements in radiation therapy, including proton therapy and stereotactic radiation, reduce side effects and improve quality of life for GI cancer.
FDA Approves Cabometyx, Another Treatment for Neuroendocrine Tumors
The FDA has approved Cabometyx for some patients 12 years old and older with previously treated neuroendocrine tumors.
Springtime Health After My Testicular Cancer Diagnosis
Experiencing spring's renewal after a cancer diagnosis, I focus on health through checkups, diet and exercise, embracing change and well-being.
AU-007 Combo Dosing Begins in Melanoma Phase 2 Trial With Opdivo
AU-007, combined with Opdivo and low-dose aldesleukin, has entered a phase 2 melanoma trial, with early data showing activity and manageable safety.
Trial of SVV-001, Opdivo and Yervoy in Neuroendocrine Tumors Launching
A phase 1 clinical trial is open for enrollment to patients with high-grade neuroendocrine tumors.
Early Detection Critical for Testicular Cancer in Young Men
April serves as Testicular Cancer Awareness Month, which is the most common type of cancer in men aged between 15 and 44 years old.
Ziftomenib Submits New Drug Application to FDA for R/R NPM1-Mutant AML
The FDA previously granted breakthrough therapy designation to ziftomenib for relapsed/refractory NPM1-mutant AML.
Phase 3 Trial Leads to FDA Approval of Cabometyx in Neuroendocrine Tumors
Based on the phase 3 CABINET trial, the FDA approved Cabometyx for some patients with previously treated neuroendocrine tumors.
NeuroSAFE May Increase Erectile Function After Prostate Cancer Surgery
Use of NeuroSAFE during prostatectomy nearly doubled the number of patients who had no or mild erectile dysfunction approximately a year later.
First Patient Dosed With KSQ-004EX In Solid Tumor Clinical Trial
KSQ-004EX is being evaluated in solid tumors including melanoma, non-small cell lung, head and neck, colorectal, pancreatic and cervical cancer.
Imdelltra May Improve Survival in Small Cell Lung Cancer
Imdelltra is associated with improvement in overall survival compared to local standard-of-care chemotherapy among patients with small cell lung cancer.
A Kidney Cancer Advocate Shares Advice for Newly Diagnosed Patients
Some cancer statistics may reflect 'backwards-looking data', making it important to stay up to date on reliable information and happenings in the space.
Knowing the Signs to Detect and Treat Testicular Cancer Early
Testicular cancer is rare but highly curable, especially with early detection; treatment varies by stage, and follow-up care supports long-term health.
Spring Forward: How I Stay Grounded and Hopeful with Lynch Syndrome
Living with Lynch isn't easy, but it's not all doom and gloom. It's a call to live deliberately.
What Role May ctDNA Have in Melanoma Management?
CURE spoke with Dr. Michael K. Wong and Dr. Diwakar Davar about the use of ctDNA for patients with melanoma, and where the field may be headed.
An Expert Breaks Down Lymphedema Following Cancer Care
Dr. Sheri Yolanda Prentiss discusses the importance of seeking early intervention to detect lymphedema following cancer care.
Melanoma Taught Me Faith, Gratitude and That Nothing Is Permanent
I was diagnosed with stage 3 melanoma at 31, faced recurrence and now share my journey to raise awareness, stay hopeful and trust in God’s plan.
FDA Approves Avastin Biosimilar Jobevne Across Several Cancer Types
The FDA has approved Jobevne, a biosimilar to Avastin, for IV use in a number of cancer types.
Managing Cancer Demands With Flexibility and a Strategic Mindset
It isn’t easy having cancer. But like gardening in a harsh climate, survival and growth come from strategies, adaptation, and patience.
FDA Grants Full Approval to Vitrakvi For NTRK-Positive Solid Tumors
Vitrakvi, first granted accelerated approval in 2018, has received full approval from the FDA.
Kaifan Zhao, AGACNP-BC, PMHNP-BC, Wins CURE’s 2025 Extraordinary Healer® Award
The 2025 Extraordinary Healer® Award was presented during the 50th Annual Oncology Nursing Society Congress, recognizing oncology nursing professionals' dedication and impact.
First Patient Dosed in Trial of CT-95 in Mesothelin-Expressing Tumors
CT-95 is being developed for cancers including pancreatic, ovarian and mesothelioma and other solid tumors.
Early Detection and Screening is Key for Esophageal Cancer
Because the five-year relative survival rate for people with esophageal cancer is approximately 22%, this makes early detection of the essence.
